Valencia, Calif., USA, and Melbourne, Australia, 20 December 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named AVITA as one of the most innovative companies of 2018. AVITA […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-12-21 00:05:132018-12-21 00:05:13AVITA Medical Named One of the Most Innovative Companies of 2018 by PM360
AmpliPhi’s wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements CATEGORY: Featured Tuesday, December 18, 2018 6:50 am EST SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “The improved manufacturing productivity that we have achieved for AB-SA01 is […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-12-18 23:01:532018-12-20 23:02:32AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development
Valencia, Calif., USA, and Melbourne, Australia, 18 December 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1,421,000 for the year ending 30 June 2018. The R&D Tax […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-12-17 23:47:352018-12-20 23:57:42AVITA Medical Announces Receipt of A$1.4 Million Research and Development Tax Credit
Valencia, Calif., USA, and Melbourne, Australia, 16 November 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has completed hiring of the U.S. sales team to support the U.S. market launch of the RECELL® System for the treatment of acute thermal burns. The full direct sales team […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-12-16 23:12:012018-12-20 23:23:18AVITA Medical Announces Hiring of Full U.S. Sales Team of Experienced Burn Professionals to Support National Launch of RECELL® System Strong market response to the RECELL System approval in advance of U.S. launch with 32 burn centers actively reviewing the product or placing commercial orders
ARECOR LIMITED (“Arecor” or “the Company”) ARECOR TO ATTEND THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Cambridge, UK., 5 December 2018: Arecor Ltd (“the Company”), the UK-based specialty pharmaceutical company that develops superior biopharmaceuticals through the application of an innovative formulation technology platform, is pleased to announce today that its executive management team, Dr Sarah […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-12-05 23:04:122019-02-13 12:28:10Arecor to attend the 37th Annual J.P. Morgan Healthcare Conference
Valencia, Calif., USA, and Melbourne, Australia, 4 December 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced an institutional placement of A$40.0 million (Institutional Placement) to fund the marketing and sales effort to support U.S. market launch of the RECELL® System, clinical and research and development to facilitate pipeline […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-12-04 23:24:092018-12-20 23:46:54AVITA Medical Announces Institutional Placement of A$40.0 Million to Support Commercialization and Pipeline Advancement Share purchase plan (SPP) also announced to allow eligible shareholders to purchase up to A$3.0 million in shares
Posted on November 14, 2018 ADC Biotechnology (ADC Bio), announces that it has secured additional funding of £2.5 million from existing investors and company management. The investment syndicate consists of Maven Capital Partners, Seneca Partners, the Development Bank of Wales and Downing LLP. The finance will be deployed to ensure the achievement of specific business goals […]
Burn surgeon presents health economic model projecting burn center will save up to USD $21 million per year treating patients with the RECELL System compared to conventional treatment Valencia, Calif., USA, and Melbourne, Australia, 13 November 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that key opinion leaders […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-11-13 03:07:452018-11-13 03:07:45Leading Burn Surgeons Present Positive RECELL® System Results at 31st Annual Southern Region Burn CME Conference and Northeast Region Burn Conference
The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the company’s expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% treatment success at the end of therapy Raised gross proceeds of $6.8 million through an […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-11-08 02:53:092018-11-13 02:54:33AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights
Brighton, United Kingdom – 1 November 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, that addresses the global problem of antimicrobial resistance (AMR), today announces it has been jointly awarded a National Biofilms Innovation Centre (NBIC) funded research collaboration with the University of Southampton. The […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-11-01 00:31:402018-11-02 00:33:42Destiny Pharma announces research collaboration with the University of Southampton targeting infections in diabetic foot ulcers and cystic fibrosis
AVITA Medical Named One of the Most Innovative Companies of 2018 by PM360
/in Avita MedicalValencia, Calif., USA, and Melbourne, Australia, 20 December 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named AVITA as one of the most innovative companies of 2018. AVITA […]
AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development
/in Armata PharmaceuticalsAmpliPhi’s wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements CATEGORY: Featured Tuesday, December 18, 2018 6:50 am EST SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “The improved manufacturing productivity that we have achieved for AB-SA01 is […]
AVITA Medical Announces Receipt of A$1.4 Million Research and Development Tax Credit
/in Avita MedicalValencia, Calif., USA, and Melbourne, Australia, 18 December 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1,421,000 for the year ending 30 June 2018. The R&D Tax […]
AVITA Medical Announces Hiring of Full U.S. Sales Team of Experienced Burn Professionals to Support National Launch of RECELL® System Strong market response to the RECELL System approval in advance of U.S. launch with 32 burn centers actively reviewing the product or placing commercial orders
/in Avita MedicalValencia, Calif., USA, and Melbourne, Australia, 16 November 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has completed hiring of the U.S. sales team to support the U.S. market launch of the RECELL® System for the treatment of acute thermal burns. The full direct sales team […]
Arecor to attend the 37th Annual J.P. Morgan Healthcare Conference
/in ArecorARECOR LIMITED (“Arecor” or “the Company”) ARECOR TO ATTEND THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Cambridge, UK., 5 December 2018: Arecor Ltd (“the Company”), the UK-based specialty pharmaceutical company that develops superior biopharmaceuticals through the application of an innovative formulation technology platform, is pleased to announce today that its executive management team, Dr Sarah […]
AVITA Medical Announces Institutional Placement of A$40.0 Million to Support Commercialization and Pipeline Advancement Share purchase plan (SPP) also announced to allow eligible shareholders to purchase up to A$3.0 million in shares
/in Avita MedicalValencia, Calif., USA, and Melbourne, Australia, 4 December 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced an institutional placement of A$40.0 million (Institutional Placement) to fund the marketing and sales effort to support U.S. market launch of the RECELL® System, clinical and research and development to facilitate pipeline […]
ADC Bio Secures Additional Equity Round Investment
/in ADC BioPosted on November 14, 2018 ADC Biotechnology (ADC Bio), announces that it has secured additional funding of £2.5 million from existing investors and company management. The investment syndicate consists of Maven Capital Partners, Seneca Partners, the Development Bank of Wales and Downing LLP. The finance will be deployed to ensure the achievement of specific business goals […]
Leading Burn Surgeons Present Positive RECELL® System Results at 31st Annual Southern Region Burn CME Conference and Northeast Region Burn Conference
/in Avita MedicalBurn surgeon presents health economic model projecting burn center will save up to USD $21 million per year treating patients with the RECELL System compared to conventional treatment Valencia, Calif., USA, and Melbourne, Australia, 13 November 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that key opinion leaders […]
AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights
/in Armata PharmaceuticalsThe company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the company’s expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% treatment success at the end of therapy Raised gross proceeds of $6.8 million through an […]
Destiny Pharma announces research collaboration with the University of Southampton targeting infections in diabetic foot ulcers and cystic fibrosis
/in Destiny PharmaBrighton, United Kingdom – 1 November 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, that addresses the global problem of antimicrobial resistance (AMR), today announces it has been jointly awarded a National Biofilms Innovation Centre (NBIC) funded research collaboration with the University of Southampton. The […]